Amyris, Inc. (NASDAQ:AMRS) is scheduled to release its earnings data after the market closes on Wednesday, August 2nd. Analysts expect Amyris to post earnings of ($1.06) per share for the quarter.

Amyris (NASDAQ:AMRS) last announced its earnings results on Monday, May 15th. The biotechnology company reported ($1.95) EPS for the quarter, missing the consensus estimate of ($1.35) by $0.60. The firm had revenue of $13 million during the quarter, compared to analyst estimates of $32.30 million. Amyris’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.55) earnings per share. On average, analysts expect Amyris to post $-3.98 EPS for the current fiscal year and $-1.63 EPS for the next fiscal year.

Amyris, Inc. (NASDAQ AMRS) opened at 3.96 on Wednesday. The stock has a 50 day moving average price of $3.35 and a 200 day moving average price of $6.47. Amyris, Inc. has a one year low of $2.63 and a one year high of $18.15. The firm’s market capitalization is $78.43 million.

In other news, Director Patrick Y. Yang purchased 300,000 shares of Amyris stock in a transaction that occurred on Friday, May 19th. The shares were acquired at an average price of $0.29 per share, for a total transaction of $87,000.00. Following the transaction, the director now owns 153,000 shares of the company’s stock, valued at approximately $44,370. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 11.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at

Several analysts recently issued reports on the stock. HC Wainwright set a $15.00 price target on shares of Amyris and gave the stock a “buy” rating in a research report on Wednesday, June 7th. Zacks Investment Research upgraded shares of Amyris from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 16th. Finally, ValuEngine lowered shares of Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $31.13.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Earnings History for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with's FREE daily email newsletter.